Isabelle Solomon
Gamida Cell (Israel) · 18 works · 1,716 citations · h-index 6
Top works
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans
- Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells
- CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
- Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
- Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control
- Abstract 3143: A novel approach to deplete Treg cells using non-IL-2 blocking anti-CD25-targeting antibodies leads to complete rejection of established tumors
- Abstract 2787: Generation of first-in-class anti-CD25 antibodies depleting Treg without interfering with IL2 signalling for cancer therapies
- Abstract A192: Non-IL-2 blocking anti-CD25-targeting antibodies: depletion of regulatory T-cells driving optimal effector response for rejection of established tumors
- Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
- 09.04 Secondary resistance to immunotherapy is associated with death and de-differentiation of activated T cells
- Agonistic anti-ICOS antibodies promote unexpected elimination of tumor infiltrating effector T cells in a FcγR-independent manner
- Abstract A101: Single-cell analysis reveals the pivotal role of the innate immune compartment in aCTLA-4 antitumor response
- 401 GDA-201, nicotinamide (NAM) expanded NK cells derived from peripheral apheresis, show unique culture kinetics and increased expansion
- Targeting regulatory T cells for therapeutic gain in cancer therapy
- Gda-201: A Cryopreserved, Readily Available Formulation of Nicotinamide-Enabled Natural Killer Cells, Shows Increased Potency and Enhanced Cytotoxicity
- P03.23 Evolution of the immune landscape within partially controlled murine melanoma
- Gene Editing/Gene Therapies: GDA-201: PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF CRYOPRESERVED NICOTINAMIDE-EXPANDED ALLOGENEIC NATURAL KILLER CELLS DEMONSTRATE AN ACTIVATED AND NON-EXHAUSTED PHENOTYPE